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Prostaglandins, Masculinization and Its Disorders: Effects
of Fetal Exposure of the Rat to the Cyclooxygenase
Inhibitor- Indomethacin
Afshan Dean, William Mungall, Chris McKinnell, Richard M. Sharpe*
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Abstract
Recent studies have established that masculinization of the male reproductive tract is programmed by androgens in a
critical fetal ‘masculinization programming window’ (MPW). What is peculiar to androgen action during this period is,
however, unknown. Studies from 20 years ago in mice implicated prostaglandin (PG)-mediation of androgen-induced
masculinization, but this has never been followed up. We therefore investigated if PGs might mediate androgen effects in
the MPW by exposing pregnant rats to indomethacin (which blocks PG production by inhibiting cyclooxygenase activity)
during this period and then examining if androgen production or action (masculinization) was affected. Pregnant rats
were treated with indomethacin (0.8 mg/kg/day; e15.5–e18.5) to encompass the MPW. Indomethacin exposure decreased
fetal bodyweight (e21.5), testis weight (e21.5) and testicular PGE2 (e17.5, e21.5), but had no effect on intratesticular
testosterone (ITT; e17.5) or anogenital index (AGI; e21.5). Postnatally, AGI, testis weight and blood testosterone were
unaffected by indomethacin exposure and no cryptorchidism or hypospadias occurred. Penis length was normal in
indomethacin-exposed animals at Pnd25 but was reduced by 26% (p,0.001) in adulthood, an effect that is
unexplained. Our results demonstrate that indomethacin can effectively decrease intra-testicular PGE2 level. However,
the resulting male phenotype does not support a role for PGs in mediating androgen-induced masculinization during the
MPW in rats. The contrast with previous mouse studies is unexplained but may reflect a species difference.
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Introduction
Masculinization by androgens is a pivotal event in the
development of a phenotypic male, and mild disorders of this
process (hypospadias, cryptorchidism) are common in human
males at birth [1–3]. In rats, there is a critical period, the
masculinization programming window (MPW), during which
sufficient testosterone, produced by the fetal testis, ‘programs’
the male reproductive tract so that it can differentiate and grow
normally after the MPW [4]. Any impairment of androgen action
during the MPW results in smaller reproductive organs and/or
abnormal function as well as decreased anogenital distance (AGD)
[4],[5]. AGD, the distance between the anus and genitalia, is
about twice as long in male rats as in females and provides a life-
long readout of androgen action during the MPW [4]. A similar
MPW may exist in humans, within the period 8–14 weeks of
gestation [4], and AGD is approximately twice as long in males as
in females at birth [6],[7] and is therefore suggested to provide a
similar read-out of fetal androgen exposure in the MPW as in the
rat [6–9].
The molecular mechanisms and androgen pathways triggered
during the MPW remain to be elucidated. Prostaglandins (PGs)
are potentially implicated based on early studies by Gupta
[10],[11] in which treatment of pregnant mice with cyclooxygen-
ase (COX) inhibitors (aspirin, indomethacin) during the period of
the MPW was shown to reduce male AGD, with the effect clearly
downstream of androgen action. PGs are lipid compounds derived
from arachidonic acid [12]. They mediate many important
biological functions, acting in a paracrine or autocrine fashion.
COX1 and COX2 are fundamental enzymes in the synthesis of
PGs from arachidonic acid. PGs are recognized to be involved in
various reproductive functions such as ovulation and implantation
[13],[14] and induction of labor [15],[16].
There is further evidence supporting a role for PGs in mediating
aspects of androgen action in the MPW. Four epidemiological
studies have shown that use of paracetamol (acetaminophen),
with/without other painkillers that interfere with PG production
(such as aspirin), by women in pregnancy during the period of the
proposed MPW, significantly increase the risk of cryptorchidism in
sons [17–20]. Rat studies have shown that inhibition of androgen
action in the MPW increases incidence of cryptorchidism [4],[21]
and, consistent with this, paracetamol and/or other prostaglandin
inhibitors (aspirin, indomethacin) have been shown to reduce
testosterone production in vitro by fetal rat testes [22]. Viewed
together, the aforementioned data makes a strong case for the
possibility that prostaglandins mediate aspects of androgen action
in the MPW, and with human health relevance. The objective of
the present study was to directly test this possibility by investigating
in the rat if inhibition of PG production by indomethacin during
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the MPW was able to interfere with normal masculinization and
thus to induce male reproductive disorders such as hypospadias or
cryptorchidism. These disorders are associated with a decrease in
androgen action during the MPW resulting in a decreased AGD
[4].
Methods
Animals and Treatments
For all studies, animals were treated humanely and with regard
for alleviation of suffering. Studies were performed according to
the Animal (Scientific Procedures) Act 1986 following specific
approval by the UK Home Office. Studies were conducted under
Project Licence PPL 60/3914 following review by the University
of Edinburgh Animal Research Ethics Committee. Wistar rats
were maintained according to UK home office guidelines and had
free access to fresh tap water and soy free diet (SDS; Dundee,
Scotland). Time-matings were established by the presence of a
vaginal plug and this was defined as embryonic day (e) 0.5. To
investigate if exposure to indomethacin can affect fetal masculin-
ization, pregnant animals were exposed to indomethacin (Sigma-
Aldrich, UK) during the MPW (e15.5–e18.5) to determine if PGs
are involved in androgen programming during this time. Animals
that were killed on e17.5 received treatment up until e16.5
whereas those sampled on e21.5 received treatment until e18.5.
The indomethacin dose of 0.8 mg/kg was selected following
preliminary studies that investigated a number of doses (2, 1 or
0.8 mg/kg) but which determined that the two higher doses
resulted in unacceptable litter loss and/or severe maternal intra-
gastric bleeding. Control dams were injected with corn oil daily in
the same time window (e15.5–e18.5). Data for male offspring
collected in fetal life were from a minimum of 6 litters per
treatment group and for postnatal studies from a minimum of 3
litters.
Tissue recovery and measurements
Control and treated rat dams were killed on either e17.5 (during
the MPW), e21.5 or allowed to give birth, and resulting offspring
then killed on either postnatal day (Pnd) 25 ( = early puberty) or
75 ( = adults). For fetal studies, pregnant dams were killed by
inhalation of CO2 followed by cervical dislocation, fetuses were
removed, and placed in ice-cold PBS (Sigma-Aldrich). E21.5
fetuses were weighed and AGD measured using digital calipers
(Faithfull Tools, Kent, UK) and the fetuses then decapitated. The
gonads were removed by microdissection from both e17.5 and
e21.5 fetuses. Tissue was either stored at280uC for PGE2 or
intratesticular testosterone ELISA assays or fixed in Bouin’s
fixative for 1 h, then transferred to 70% (v/v) ethanol and
processed into paraffin wax blocks using standard procedures and
an automatic tissue processor.
Postnatal animals were killed by inhalation of CO2 followed by
cervical dislocation. Blood was collected from the heart into a
heparinized syringe and the plasma separated and stored
at220uC. Bodyweight and AGD were measured before dissection
of the penis and gonads, which were weighed. The length of the
dissected penis was measured by digital callipers as described
previously [23]. Tissue was fixed in Bouin’s fixative for 6 h before
being transferred to 70% (v/v) ethanol and embedded in paraffin
wax as above.
Prostaglandin E2 (PGE2) measurement
PGE2 was measured in the fetal gonads from control and
indomethacin-treated groups to determine if effective exposure of
the fetus had occurred. For collection of e17.5 samples treatment
protocol described above was followed, whereby dams were
treated on e15.5, e16.5 and e17.5 but then pups were removed 4 h
after maternal injection on e17.5, gonads dissected and frozen
at280uC. Although this showed significant suppression by
indomethacin of testicular PGE2 levels on e17.5 (ie during the
MPW), to provide further reassurance that effective exposure of
the fetus was occurring we undertook a similar study outside of the
MPW on e21.5. For this study, dams were treated with
indomethacin only on e20.5 and e21.5 and culled 4 h after the
final treatment (see Fig. S1). Gonads from each animal were
pooled and homogenized in 0.05 mM Tris/HCL PH 7.4 and
PGE2 levels were determined in each sample using Detect X
Prostaglandin E2 Enzyme Immunoassay kit, according to manu-
facturer’s instructions (Arbor Assays, Michigan, US). PGE2 levels
were read using an optical microplate reader (Labsystems,
MutiSKan Ex, UK) and results analyzed using MasterPlexTM
ReaderFit software (MiraiBio Group, Hitachi Ltd).
Testosterone measurements
Fetal intratesticular testosterone levels were measured by
competitive radioimmunoassay (RIA). All other details were as
described previously [24]. Pnd25 and Pnd75 plasma levels of
testosterone were measured using an enzyme-linked immunosor-
bent assay adapted from an earlier RIA method. This has been
described in detail previously [25].
Statistics
Data are expressed as means 6SEM. All analyses used
GraphPad Prism. Rat data was analyzed using one-way ANOVA
followed by the Bonferroni post-test or using students t-test as
appropriate (version 5; GraphPad Software Inc., San Diego, CA,
USA). The presented rat data used each animal as the unit rather
than the litter, but re-analysis of the data using litter means did not
alter any of the main findings. As there were significant treatment
effects on bodyweight that may affect AGD, the latter was divided
by the cube root of bodyweight to determine the anogenital index
(AGI), and this was used in graphs and for statistical analyses. Data
for testosterone was log-transformed prior to analysis to remove
heterogeneity of variance.
Results
Fetal effects of exposure to indomethacin
At 4 h after maternal indomethacin treatment, PGE2 levels in
the fetal testis were significantly decreased at e17.5 (during the
MPW) when compared to controls (Fig. 1A), indicating effective
exposure of the fetus. To provide further reassurance on this, we
established separately that our indomethacin treatment protocol
suppressed PGE2 levels in the fetal testis on e21.5 (Fig S1).
However, fetal exposure to indomethacin during the MPW did not
significantly alter intratesticular testosterone (ITT) levels at e17.5,
in comparison to vehicle exposed animals (Fig 1B). Testosterone
levels/androgen action during the MPW is reflected in AGD/AGI
measurements from e21.5 onwards [4],[5]. In keeping with the
data for e17.5 ITT, fetal indomethacin exposure during the MPW
did not affect AGI at e21.5 (Fig. 2A), but did decrease fetal body
weight of e21.5 male fetuses (Fig. 2B). Furthermore, exposure to
indomethacin caused a significant decrease (27%) in fetal testis
weight at e21.5 and this decrease occurred despite the fact that
indomethacin treatment had ceased after e18.5 (Fig. 2C). If
indomethacin treatment (0.8 mg.kg/day) was administered for a
longer period (e15.5–e20.5), a similar decrease was found in testis
weight (data not shown).
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Postnatal effects of fetal exposure to indomethacin
Offspring were evaluated on Pnd25 and Pnd75. In utero
exposure to indomethacin did not result in hypospadias or
cryptorchidism in any offspring (for vehicle N=0/56; for
indomethacin 0/26).
By puberty (Pnd25), indomethacin exposed males were signif-
icantly heavier (,24%) than vehicle exposed control animals, and
this difference (,23%) was still evident at Pnd75 (Fig. 3A). AGI at
Pnd25 and Pnd75 was unaffected by fetal exposure to indometh-
acin (Fig. 3B) and in utero exposure to indomethacin did not
significantly alter plasma levels of testosterone at either age (Fig. 4).
Testis weight in indomethacin-exposed animals was comparable
to controls at both ages (Fig. 5A) and there were no gross
morphological changes in the testis (data not shown). No change
was found in penile length at Pnd25 in indomethacin exposed
animals but, unexpectedly, in adulthood, males exposed in utero to
indomethacin, had a significantly shorter penile length (26%
reduction) than controls (Fig. 5B).
Discussion
Two lines of evidence prompted the present studies. The first
was the clear demonstration in mice that exposure to PG
inhibitors, such as indomethacin, during the MPW inhibited
masculinization (AGD) [10],[11]. The second was evidence from
human studies that exposure to acetaminophen (6 other
painkillers) during the presumptive MPW period increased
incidence of cryptorchidism in male offspring [17–20], supported
by rat experimental data that treatment with acetaminophen
(during the MPW) reduced AGD [19]. A common pathway that
might link these findings would be inhibition of PG production,
although acetaminophen can also exert effects via other (incom-
pletely understood) mechanisms [26]. We used the rat, in which
we have established robust information on timing of the MPW and
its susceptibility to disruption [4],[5],[25] to replicate earlier
mouse studies [10],[11] and to identify whether interference with
PG production/action during the MPW was likely to lead to
disorders/impairment of masculinization. Our findings do not
support such a role for PGs in the rat.
Despite replicating the treatment protocol of Gupta [10],[11],
though with a slightly lower dose of indomethacin (0.8 mg/kg
Figure 1. Effects of maternal exposure to vehicle or indometh-
acin (0.8 mg/kg/day) on (A) testicular PGE2 levels at e17.5 and
(B) intra-testicular testosterone content at e17.5. Values are
means 6 SEM for N=5 for the top graph and N=7–28 for the bottom
graph, from a minimum of 3 litters. **p,0.01, in comparison with
respective control.
doi:10.1371/journal.pone.0062556.g001
Figure 2. Effects of maternal exposure to vehicle or indometh-
acin (0.8 mg/kg/day; e15.5–e18.5) on anogenital index (A),
bodyweight (B) and testis weight (C) at e21.5. Values are means
6 SEM for N= 7–45 from a minimum of three litters ***p,0.001 in
comparison with respective control.
doi:10.1371/journal.pone.0062556.g002
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versus 1 mg/kg) because of concerns about confounding maternal
toxic effects observed with the higher dose, we were unable to
demonstrate any interference with masculinization, in terms of
AGD/AGI or reproductive development. One obvious explana-
tion would be that in rats indomethacin did not transfer across the
placenta as readily as in mice. We cannot exclude this possibility
completely, but our demonstration that indomethacin can
decrease PGE2 in the fetal testis 4 h later suggests that placental
transfer of indomethacin does occur. The decrease in PGE2
caused by indomethacin exposure during the MPW did not affect
ITT levels during the MPW, nor plasma testosterone postnatally
nor AGI, suggesting that PGE2 is not crucial for correct and full
masculinization in rats. The stark difference in effects of
indomethacin in the rat (present studies) and in the mouse
[10],[11] is unexplained and is presumed to reflect a species
difference. The absence of any effect of indomethacin on ITT in
our studies, contrasts with studies in vitro that showed mild
inhibition of testosterone production by e14.5 fetal rat testis
cultures exposed to 10, but not to 1, micromolar indomethacin for
72 h [22]. This might indicate that higher levels of indomethacin
exposure can suppress ITT, but to obtain higher exposure in vivo
was not feasible in our rat studies because of maternal toxicity
effects.
Some significant effects in males were seen after fetal
indomethacin exposure, such as a decrease in testis weight at
e21.5, although this corrected postnatally; we are currently
investigating the cause of this reduction. One completely
unexplained effect of in utero indomethacin exposure was the
finding of a significant decrease in adult (final) penile length
whereas penis length at Pnd25 was normal. Our previous studies
have shown that penis length is programmed by androgen action
in the MPW [5],[27],[28], although its growth after this time
Figure 3. Effects of maternal exposure to vehicle or indometh-
acin (0.8 mg/kg/day; e15.5–e18.5) on bodyweight (A), and
anogenital index (B) at Pnd25 and Pnd75 (adulthood). Values
are means 6 SEM for N= 6–20 from a minimum of three litters.
**p,0.01 in comparison with respective control.
doi:10.1371/journal.pone.0062556.g003
Figure 4. Effects of maternal exposure to vehicle or indometh-
acin (0.8 mg/kg/day; e15.5–e18.5) on serum testosterone levels
at Pnd25 and Pnd75 (adulthood). Values are means 6 SEM for
N= 4–13 animals from a minimum of two litters.
doi:10.1371/journal.pone.0062556.g004
Figure 5. Effects of maternal exposure to vehicle or indometh-
acin (0.8 mg/kg/day; e15.5–e18.5) on testis weight (A), and
penis length (B) at Pnd25 and Pnd75 (adulthood). Values are
means 6 SEM for N = 6–20 from a minimum of three litters.
***p,0.0001, in comparison with respective control.
doi:10.1371/journal.pone.0062556.g005
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period is also androgen-dependent [27]. As ITT during the MPW
and AGI at all ages was normal in indomethacin-exposed animals,
and postnatal blood testosterone levels were normal at the two
ages investigated, there is no obvious explanation for this finding.
It is possible that fetal indomethacin exposure could have led to
transient reduction in gonadotrophin secretion postpubertally,
with the resulting lowering of testosterone leading to reduced
penile growth, but a mechanism for such a change is not obvious.
It should be noted also that, although penis length can vary in
adult rats, the average length found in adult indomethacin-
exposed animals lay below the range of values that we have seen in
controls.
In conclusion, in utero indomethacin exposure did not result in
overt inhibition of masculinisation nor the induction of recogniz-
able masculinisation disorders in rats that occur with similar timed
exposure to other compounds (e.g. flutamide, dibutyl phthalate)
[5],[27] [29],[30]. Although some effects were found, such as a
decrease in fetal testis weight and adult penile length, overall
masculinisation was unaffected. In summary it can be concluded
that exposure to indomethacin during the MPW, at a dose
sufficient to cause a decrease in intra-testicular PGE2, is not
involved in androgen driven masculinisation during the MPW.
More detailed studies as to the role of PGs in penile development
are required.
Supporting Information
Figure S1 Effect of maternal exposure to vehicle or
indomethacin (0.8 mg/kg/day) on testicular PGE2 levels
at e21.5 in rats. Values are means 6 SEM for N=5. *p,0.05,
in comparison with respective control. Treatment details are
described in Materials & Methods.
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